Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Non-Current Assets (2022 - 2025)

Atara Biotherapeutics' Non-Current Assets history spans 4 years, with the latest figure at $8.0 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 81.85% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $66.7 million, down 68.03%, while the annual FY2025 figure was $8.0 million, 81.85% down from the prior year.
  • Non-Current Assets reached $8.0 million in Q4 2025 per ATRA's latest filing, down from $11.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $89.1 million in Q2 2022 to a low of $8.0 million in Q4 2025.
  • Average Non-Current Assets over 4 years is $56.2 million, with a median of $61.2 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: dropped 6.02% in 2023, then crashed 81.85% in 2025.
  • A 4-year view of Non-Current Assets shows it stood at $81.3 million in 2022, then dropped by 21.77% to $63.6 million in 2023, then tumbled by 30.54% to $44.2 million in 2024, then plummeted by 81.85% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Non-Current Assets are $8.0 million (Q4 2025), $11.7 million (Q3 2025), and $12.1 million (Q2 2025).